Plasma membrane as target of alkylating agents

Area of Science:

• Molecular Biology
• Cell Biology
• Pharmacology

Background:

• Nitrogen mustard resistance in Walker cells does not correlate with DNA interstrand cross-link frequency or removal rates.
• Alkylating agents are used in cancer therapy, but their precise mechanisms of action and resistance are not fully understood.

Purpose of the Study:

• To investigate the mechanisms underlying nitrogen mustard resistance in Walker cells.
• To explore the role of DNA cross-linking and plasma membrane enzyme activity in alkylating agent cytotoxicity.
• To assess potential synergistic effects between alkylating agents and inhibitors of growth factor pathways.

Main Methods:

• Comparison of DNA interstrand cross-linking and removal in resistant and sensitive cell lines.
• Treatment with chlorambucil-polyethyleneimine conjugates to modulate DNA cross-linking.
• Assessment of alkylating agent effects on plasma membrane transport systems (Na+/K+/Cl- cotransport, Na+/H+-antiport).
• Evaluation of drug synergism using phospholipase C inhibitors (mepacrine) and calmodulin inhibitors (chlorpromazine, flunarizine).

Main Results:

• Resistant cells showed similar DNA cross-linking and removal rates as sensitive cells, suggesting DNA damage alone is insufficient for resistance.
• Alkylating agents interfered with key plasma membrane enzymes, including furosemide-sensitive Na+/K+/Cl- cotransport and Na+/H+-antiport.
• Mepacrine, chlorpromazine, and flunarizine amplified the cytotoxic effects of nitrogen mustard, indicating synergism.

Conclusions:

• DNA cross-links are not the sole determinant of alkylating agent cytotoxicity; other mechanisms are involved.
• Plasma membrane enzyme inhibition represents a significant mechanism of action for alkylating agents.
• Inhibitors targeting early growth-factor-controlled reactions can synergize with alkylating agents, offering potential therapeutic strategies.